Development and validation of a liquid chromatography tandem mass spectrometry quantification method for 14 cytotoxic drugs in environmental samples.
Antineoplastic Agents
/ chemistry
Chromatography, High Pressure Liquid
/ methods
Cyclophosphamide
/ analysis
Cytarabine
/ analysis
Deoxycytidine
/ analogs & derivatives
Doxorubicin
/ analysis
Environmental Pollutants
/ chemistry
Occupational Exposure
/ analysis
Paclitaxel
/ analysis
Sensitivity and Specificity
Tandem Mass Spectrometry
/ methods
Gemcitabine
Journal
Rapid communications in mass spectrometry : RCM
ISSN: 1097-0231
Titre abrégé: Rapid Commun Mass Spectrom
Pays: England
ID NLM: 8802365
Informations de publication
Date de publication:
28 Feb 2020
28 Feb 2020
Historique:
received:
08
07
2019
revised:
06
09
2019
accepted:
06
09
2019
pubmed:
14
9
2019
medline:
18
9
2020
entrez:
14
9
2019
Statut:
ppublish
Résumé
Cytotoxic drug preparation in hospital pharmacies is associated with chronic occupational exposure leading to a risk of adverse effects. The objective was to develop and validate a quantification method for the following cytotoxic drugs in environmental wipe samples: cyclophosphamide, ifosfamide, cytarabine, dacarbazine, docetaxel, paclitaxel, doxorubicin, epirubicin, etoposide, 5-fluorouracil, gemcitabine, irinotecan, methotrexate and pemetrexed. The quantification method was developed using liquid chromatography coupled to tandem mass spectrometry and a wiping technique using viscose swabs. Linearity, accuracy, precision, limit of quantification, specificity and stability were assessed, from swab desorbed solution, to validate the analytical method, with respect to ICH guidelines. Environmental samples were collected by wiping five work surfaces of 225 cm The quantification method was linear over the calibration range with a lower limit of quantification ranging from 0.5 to 5.0 ng mL This quantification method for 14 cytotoxic drugs was successfully applied to environmental contamination monitoring and could therefore be a useful tool for monitoring and toxicological studies.
Substances chimiques
Antineoplastic Agents
0
Environmental Pollutants
0
Cytarabine
04079A1RDZ
Deoxycytidine
0W860991D6
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Paclitaxel
P88XT4IS4D
Gemcitabine
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e8594Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Cavallo D, Ursini CL, Perniconi B, et al. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat Res. 2005;587(1-2):45-51.
Villarini M, Dominici L, Piccinini R, et al. Assessment of primary, oxidative and excision repaired DNA damage in hospital personnel handling antineoplastic drugs. Mutagenesis. 2011;26(3):359-369.
Ladeira C, Viegas S, Pádua M, et al. Assessment of genotoxic effects in nurses handling cytostatic drugs. J Toxicol Environ Health A. 2014;77(14-16):879-887.
Moretti M, Grollino MG, Pavanello S, et al. Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: A multicentric approach. Int Arch Occup Environ Health. 2015;88(6):683-695.
Hansen J, Olsen JH, Larsen AI. Cancer morbidity among employees in a Danish pharmaceutical plant. Int J Epidemiol. 1994;23(5):891-898.
IARC. IARC Monographs on the evaluation of carcinogenic risks to humans, 2012.
Sessink PJ, Sewell GJ, Vandenbroucke J. Preventing occupational exposure to cytotoxic and other hazardous drugs. European Policy Recommendations; 2016. https://www.europeanbiosafetynetwork.eu/wp-content/uploads/2016/05/Exposure-to-Cytotoxic-Drugs_Recommendation_DINA4_10-03-16.pdf
Kiffmeyer TK, Schmidt KG, Schöppe G, Sessink PJM. Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: Implications for occupational safety. Pharm J. 2002;268:331-337.
Fransman W, Vermeulen R, Kromhout H. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: A pilot study. Ann Occup Hyg. 2004;48(3):237-244.
Rajan-Sithamparanadarajah R, Roff M, Delgado P, et al. Patterns of dermal exposure to hazardous substances in European Union workplaces. Ann Occup Hyg. 2004;48(3):285-297.
Turci R, Micoli G, Minoia C. Determination of methotrexate in environmental samples by solid phase extraction and high performance liquid chromatography: Ultraviolet or tandem mass spectrometry detection? Rapid Commun Mass Spectrom. 2000;14(8):685-691.
Micoli G, Turci R, Arpellini M, Minoia C. Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001;750(1):25-32.
Brouwers EE, Huitema AD, Bakker EN, et al. Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry. Int Arch Occup Environ Health. 2007;80(8):689-699.
Jeronimo M, Colombo M, Astrakianakis G, Hon CY. A surface wipe sampling and LC-MS/MS method for the simultaneous detection of six antineoplastic drugs commonly handled by healthcare workers. Anal Bioanal Chem. 2015;407(23):7083-7092.
Maeda S, Miwa Y. Multicomponent high-performance liquid chromatography/tandem mass spectrometry analysis of ten chemotherapeutic drugs in wipe samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;921-922:43-48.
Nussbaumer S, Geiser L, Sadeghipour F, et al. Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces. Anal Bioanal Chem. 2012;402(8):2499-2509.
ICH Q2(R1). Validation of Analytical Procedures: Text and Methodology. EMEA. 2005. http://www.gmp-compliance.org/guidemgr/files/Q2(R1).PDF
FDA. Analytical Procedures and Methods Validation for Drugs and Biologics - Guidance for Industry. In:2015.
Chouquet T, Acramel A, Sauvageon H, et al. Mutagenicity assessment of environmental contaminations in a hospital centralized reconstitution unit. Ecotoxicol Environ Saf. 2018;165:174-181.
Connor TH, Zock MD, Snow AH. Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: Methodology and recommendations. J Occup Environ Hyg. 2016 Sep;13(9):658-667.
Bobin-Dubigeon C, Amiand M, Percheron C, et al. A new, validated wipe-sampling procedure coupled to LC-MS analysis for the simultaneous determination of 5-fluorouracil, doxorubicin and cyclophosphamide in surface contamination. J Anal Toxicol. 2013;37(7):433-439.
Sottani C, Turci R, Schierl R, et al. Simultaneous determination of gemcitabine, taxol, cyclophosphamide and ifosfamide in wipe samples by high-performance liquid chromatography/tandem mass spectrometry: Protocol of validation and uncertainty of measurement. Rapid Commun Mass Spectrom. 2007;21(7):1289-1296.
Crul M, Simons-Sanders K. Carry-over of antineoplastic drug contamination in Dutch hospital pharmacies. J Oncol Pharm Pract 2018;24(7): 483-489.
Fleury-Souverain S, Mattiuzzo M, Mehl F, et al. Evaluation of chemical contamination of surfaces during the preparation of chemotherapies in 24 hospital pharmacies. Eur J Hosp Pharm. 2015;22(6):333-341.
Schierl R, Bohlandt A, Nowak D. Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann Occup Hyg. 2009;53(7):703-711.
Crauste-Manciet S, Sessink PJ, Ferrari S, Jomier JY, Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg. 2005;49(7):619-628.
Berruyer M, Tanguay C, Caron NJ, Lefebvre M, Bussieres JF. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow-up study. J Occup Environ Hyg. 2015;12(2):87-94.